Combinatorial Biosynthesis of Novel Bioreductive Agents
Award last edited on: 5/6/03

Sponsored Program
Awarding Agency
Total Award Amount
Award Phase
Solicitation Topic Code

Principal Investigator
Yingqing Mao

Company Information

Acera Biosciences Inc

1479 Gortner Avenue Suite 240
St Paul, MN 55108
   (612) 624-3071
Location: Single
Congr. District: 04
County: Ramsey

Phase I

Contract Number: 1R43GM062691-01A2
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
Phase I Amount
The structural and biosynthetic similaritybetween FR900482 and mitomycin (MC) group of antitumor antibiotics makes it promising to rationally create novel mitomycin/FR900482 hybrids through combinatorial biosynthesis. After successful identification of both MC and FR900482 biosynthetic gene clusters, Acera Biosciences now sets to create such potent bioreductive agents through manipulating these pathways. The long-term goal is to generate large libraries of novel hybrids to eventually find compounds with increased tumor specificity and reduced systemic toxicity. The specific aims in this project include 1). Production of novel C6 methyl FR900482 derivatives by MC carbonyl reduction enzyme Mmcl. 2). Creation of novel chimeric MC/FR900482 hybrids. 3). Development of a multiplasmid system for further biosynthetic pathway design. Dozens of novel MC/FR900482 hybrids are expected to be generated in this proposal. The compounds with MC quinone and FR900482 hemiketal functions will be of special interests for making more potent anticancer agents. PROPOSED COMMERCIAL APPLICATION: This project is to create dozens of novel anticancer antibiotics based on the sequencing data accumulated in Acera Biosciences. More potent mitomycin/FR900482 hybrids are expected to be generated to have stronger anticancer activity and yet unobtainable through chemical synthesis methods.

Thesaurus Terms:
antineoplastic antibiotic, combinatorial chemistry, drug design /synthesis /production, gene expression, mitomycin, reducing agent alkylation, biosynthesis, biotherapeutic agent, quinone molecular cloning

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
Phase II Amount